Clinical Trial

Matrion Decellularized Placental Membrane Versus Conventional Wound Management in Subjects With Diabetic Foot Ulcers

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated December 10, 2025 (before its estimated May 2026 completion). Its status may not reflect the trial's current state.
Summary
This study will evaluate Matrion™ (LifeNet Health, Inc., Virginia Beach, VA), a placental membrane product, as a treatment for diabetic foot ulcers compared to conventional wound care. Matrion is derived from donated human birth tissue and includes both the amniotic and chorionic layers, along with the trophoblast layer. It is minimally processed using a proprietary decellularization method and terminally sterilized to ensure the membrane is acellular and sterile, making it suitable for surgical applications.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-08-07; most recent amendment 2025-12-09.
Trial Details
NCT Number NCT07116876
Lead Sponsor LifeNet Health
Conditions Diabetic Foot Ulcer (DFU), Lower Extremity
Enrollment 120 participants
Start Date 2025-06-26
Primary Completion 2026-05 (estimated)
Study Completion 2026-06 (estimated)
Updated on ClinicalTrials.gov 2025-12-10